Reason for request
The actual benefit of XARELTO (rivaroxaban) is substantial in the treatment of deep venous thrombosis (DVT) and in the prevention of recurrence of DVT and pulmonary embolism (PE) following acute DVT in adults.
Clinical Added Value
|no clinical added value||
XARELTO does not provide an improvement in actual benefit (IAB level V) in the treatment of acute deep venous thrombosis and in the prevention of the recurrence of DVT and pulmonary embolism (PE).